Clear Cell Renal Cell Carcinoma Clinical Trials

170 clinical trials for Clear Cell Renal Cell Carcinoma across international registries, including 38 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study — RECRUITING · PHASE1
• A Study of MGC026 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) — RECRUITING · PHASE2
• A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) — RECRUITING · PHASE2
• Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer — RECRUITING · PHASE3
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors — RECRUITING · PHASE1
• REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma — RECRUITING · PHASE1
• Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma — RECRUITING · PHASE1
• Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma — RECRUITING · PHASE1
• Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC — RECRUITING · PHASE1
• Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma — RECRUITING · PHASE1
• A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors — RECRUITING · PHASE1
• Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases — RECRUITING · PHASE2
• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors — RECRUITING · PHASE1
• A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma — RECRUITING · PHASE1
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — RECRUITING · PHASE1
• An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer — RECRUITING · PHASE2
• Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery — RECRUITING · PHASE2
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors — RECRUITING · PHASE1
• Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC) — RECRUITING · PHASE2
• Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC — RECRUITING · PHASE2
• Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma — RECRUITING
• A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body — RECRUITING · PHASE1
• An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma — RECRUITING · PHASE2
• Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma — RECRUITING · PHASE2
• Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC — RECRUITING · PHASE2
• Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC — RECRUITING · PHASE2
• [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma — RECRUITING · PHASE1
• A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit — RECRUITING · PHASE1
• 68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses — RECRUITING · PHASE2
• A Beta-only IL-2 ImmunoTherapY Study — RECRUITING · PHASE1
• Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC) — RECRUITING
• Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma — RECRUITING
• 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study — RECRUITING · PHASE3
• Combination of Toripalimab and JS004 Therapy for ccRCC — RECRUITING · PHASE2
• 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma — RECRUITING · NA
• 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC. — RECRUITING · PHASE2
• Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma — RECRUITING
• A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy — TERMINATED · PHASE2
• Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery — ACTIVE_NOT_RECRUITING · PHASE3
• Study of XmAb 819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma — TERMINATED · PHASE1
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study — ACTIVE_NOT_RECRUITING · PHASE3
• Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study — ACTIVE_NOT_RECRUITING · PHASE2
• Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 — ACTIVE_NOT_RECRUITING · PHASE2
• Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) — ACTIVE_NOT_RECRUITING · PHASE1
• CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC — NOT_YET_RECRUITING · PHASE2
• Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors — COMPLETED · PHASE1
• Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study — COMPLETED

Refine this search